A treatment for multi-drug resistant tuberculosis could soon become more accessible for millions of people worldwide.
1:30Mark Kauzlarich/Bloomberg via Getty Images
& Johnson, which makes and markets bedaquiline under the brand name Sirturo, had planned to utilize a secondary patent to extend their control of it until the end of 2027, advocates say.& Johnson's patent extension on bedaquiline and rallied his 4.5 million Twitter followers to pressure the company to change course.
The availability of the generic drug could provide six million people with treatment over the next four years, according to Carole Mitnick, Sc.D., a professor of global health and social medicine at Harvard Medical School and a senior research associate at Partners in Health.& Johnson said the partnership was already in the works prior to the media uproar and that it was "false to suggest" that patents were being used to prevent broader access to bedaquiline.
Patents serve a key role, however, by incentivizing innovation. "Companies fund an extraordinary amount in researching and producing and we want to encourage companies to engage in that research. The patent is a reward for that successful research," Feldman added. "When I was there, I met a young man who looked to be my son's age, who looked 9 at the time but was in fact 16 and was just really emaciated, stunted by really severe multi-drug resistant tuberculosis," said Green.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Millions could soon have access to life-saving tuberculosis drug following online uproarA treatment for multi-drug resistant tuberculosis could soon become more accessible for millions of people worldwide.
Read more »
13 Films That Forked Out Millions And Millions Of $$$ For Only A Few Minutes Of Footage'We shot one entire night for four seconds of film.'
Read more »
Johnson & Johnson must pay $18.8 million to California cancer patient in baby powder suit | CNN BusinessJohnson & Johnson must pay $18.8 million to a California man who said he developed cancer from exposure to its baby powder, a jury decided on Tuesday, a setback for the company as it seeks to settle thousands of similar cases over its talc-based products in US bankruptcy court.
Read more »
Johnson & Johnson must pay $18.8 million to California cancer patient in baby powder suitJohnson & Johnson must pay $18.8 million to a California man who said he developed cancer from exposure to its baby powder, a jury decided on Tuesday, a setback for the company as it seeks to settle thousands of similar cases over its talc-based products in US bankruptcy court.
Read more »
Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surgeThe results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based baby powder and other products caused cancer.
Read more »
Surge in Heart Procedures Helps Drive Johnson & Johnson RevenueA surge in heart procedures and higher demand for cold and flu medicines helped Johnson & Johnson report solid gains in revenue and profit for the second quarter
Read more »